

# INVITATION

## 26 September 2024

# ECP as monotherapy and combination partner

## Congress Centrum Würzburg, Germany

This information is intended for healthcare professionals in Europe

## Agenda

**Time: 16:45 – 17:45**

- 
- Moderator:** Prof. Chalid Assaf, Helios Hospital Krefeld
- 16:45 – 17:05 **ECP and Mogamulizumab**  
Prof. Jan Nicolay, University Hospital Mannheim
- 17:05 – 17:25 **The role of ECP in the treatment landscape of chronic GvHD – Focus on cutaneous manifestations**  
Prof. Robert Zeiser, Medical University of Freiburg
- 17:25 – 17:45 **Panel Discussion**  
Prof. Jan Nicolay, University Hospital Mannheim  
Prof. Robert Zeiser, Medical University of Freiburg  
Prof. Chalid Assaf, Helios Hospital Krefeld

*ECP: Extracorporeal Photopheresis, GvHD: Graft versus Host Disease*

*All speakers are subject to contract.*

***This is a commercial programme run by Therakos (UK) Ltd,  
a Mallinckrodt Company.***

[Privacy policy](#)

Follow the  
Therakos Institute



For more information on THERAKOS ECP Immunomodulation™ please visit [www.therakos.eu](http://www.therakos.eu)  
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

© 2024 Mallinckrodt. DE-2400021 April 2024.

*Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our privacy policy provides additional information.*